SEUD-EVENTS-LOGO
SEUD RENDEZ-VOUS!

SEUD RENDEZ-VOUS

SEUD, in collaboration with Gedeon Richter, is pleased to launch a new set of monthly meetings (SEUD RENDEZ VOUS) with the main theme being information related to the new class of GnRH oral antagonists:

During the next 5 months, we will have the pleasure to meet with the best experts every last Thursday of the month at 6pm to discuss all topics related to this class and its indications.

Join us in this series of webinars to be part of the discussion related to this new class and its use in your practice!

We look forward to seeing you,

SEUD

In collaboration with

Explore SEUD Rendez-vous!

SEUD Rendez-vous #1 - July 29th, 2021

Introduction to the new class of GnRH oral antagonists for the treatment of Uterine Fibroids and endometriosis

Date: July 29th 2021 at 6 PM (GMT+2)

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

PROGRAM

Introduction to the new class of GnRH oral antagonists for the treatment of Uterine Fibroids and endometriosis

Chair: Prof. Felice Petraglia (Italy)

  • General overview of the available GnRH oral antagonists including class effect, general indications and safety.
    Prof. Jasper Verguts (Belgium)
  • Analysis of safety and efficacy of different compounds based on published data.
    Dr. Josep Estadella (Spain)
Register in less than a minute

to have a full and free access

to the SEUD RENDEZ-VOUS!

Lives and replays!

ABOUT THE EXPERTS:
Felice-Patraglia-dr-2
Chair : Prof. Felice Petraglia, Italy

Professor of Obstetrics and Gynecology at the University of Florence and Chief of the Maternal – Infancy Department, Careggi Hospital, Florence (Italy).

He is Editor-in-Chief of Human Reproductive Update (IF: 11.7), and Section Head of Reproductive Endocrinology and Infertility of Faculty 1000 Medicine. He is Member of the Editorial Board of Reproductive Sciences, Journal of Endometriosis and Pelvic Pain Disorders, Gynecological Endocrinology. Professor Petraglia has also co-edited 27 scientific volumes and authored more than 700 peer-reviewed papers in International Scientific Journals.

Jasper-Verguts
Prof. Jasper Verguts, Belgium

Prof. Verguts graduated from the University of Leuven in 2004 as a medical doctor where he first became a fellow in uro-gynecology and later in gynecologic oncology. He defended his doctoral in 2011 “Can prevention of mesothelial damage during endoscopic surgery decrease adhesion formation and tumor implantation”. He started working as an endoscopic gynecologist in the Jessa Hospital Hasselt in 2013, where he is currently holding the position of head of clinic in benign gynecology. In 2020 he started teaching at the University of Hasselt. His major fields of interest are myoma’s, urogynecology and endometriosis.

Estadella
Dr. Josep Estadella, Spain

Dr. Josep Estadella was born in Barcelona (Spain). He graduated from the Universitat Autonoma de Barcelona Faculty of Medicine in 2003 and achieved the Gyn&Obs specialization on Hospital de la Santa Creu i Sant Pau (Barcelona) in 2008. Since then, he has been a staff member of the Obstetrics and Gynecology Department on that Hospital. He is also professor of the Universitat Autonoma de Barcelona’s Department of Obstetrics and Gynecology since 2010 and is devoted to the teaching of future doctors. He holds a Master’s Degree in Education and ICT from Universitat Oberta de Catalunya (Spain).

His main area of interest is the benign gynecologic pathology, focusing on uterine fibroids. He is the myoma Unit coordinator of his Hospital, a multidispciplinar unit that embraces all the different points of view of this prevalent disease (includinggynecological surgeons, clinicians, gynecological sonographers, radiologists, ART physicians and trainees). Since 2019 he has been interested in the field of eHealth technologies and is involved in several research projects on this topic.

He has published several papers in international journals such as Fertility and sterility, JMIG, Gynecological Endocrinology or European Journal of Obstetrics & Gynecology and reproductive biology, and collaborates as a reviewer for different journals (International Journal of Obstetrics and Gynecology, Clinical and Experimental Obstetrics & Gynecology, Clinica e Investigacion en Ginecologia y Obstetricia). He has been invited as a keynote speaker and chairman in national and international conferences including SEUD, COGI and ESG.

He is also a member of different medical societies, including SEUD, ESGE, Spanish Gynecologic Endoscopic Society and is a board member of the Catalan society of Gynecology and Obstetrics’ Hysteroscopy Group.

SEUD Rendez-vous #2 - August 26th, 2021

Focus on Relugolix Combination Therapy in the management of Uterine Fibroids

August 26th, 2021 at 6 PM (GMT+2)

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

PROGRAM

Focus on Relugolix Combination Therapy in the management of Uterine Fibroids

Chair: Prof. Peyman Hadji (Germany)

  • Overview of Liberty phase III program in Uterine Fibroids.
    Prof. Roberta Venturella (Italy)
  • Long term effect, BMD, bleeding control and anovulation.
    Prof. Janos Zatik (Hungary)
Register in less than a minute

to have a full and free access

to the SEUD RENDEZ-VOUS!

Lives and replays!

ABOUT THE EXPERTS:
Hadji-Peyman-Pr
Chair : Prof. Peyman Hadji, Germany

Prof. Peyman Hadji obtained his medical degree from the University of Frankfurt, Germany, in 1990, and went on to complete his postgraduate training in obstetrics and gynaecology at the Hamburg Institute of Endocrinology and Reproductive Medicine and the Philipps-University of Marburg, where he received his PD in 2001. In June 2006, he was appointed as a full Professor of Medicine at the Philipps-University of Marburg. From 2014-2018, Dr. Hadji was the head of the department of bone oncology, endocrinology and reproductive medicine at the Krankenhaus Nordwest in Frankfurt, Germany. Since October 2018, Dr. Hadji is the head of the Frankfurt Centre of Bone Health.

His current research interest is on the management of women with breast cancer, with a special focus on cancer induced bone loss (CIBL), as well as studies on side-effect management in cancer therapies and outcome research. He is the first author of a recent practical guidance for the management of aromatase inhibitor-associated bone loss of seven international societies. Dr. Hadji is also a co-author of the ESMO 2021 practice guidelines on bone health in cancer patients. He is additonally a co-author of the guidance on the use of bisphosphonates in solid tumours, a consensus recommendation from the second Cambridge conference on advancing treatment for metastatic bone cancer and a clinical experience and treatment recommendation on aromatase inhibitor-induced arthralgia. In addition to this, Dr. Hadji has performed a number of studies on compliance and persistence in oncology and osteoporotic therapies, and is involved in several clinical studies on different pharmacological interventions for osteoporosis including bisphosphonates, denosumab, parathyroid hormones, raloxifene, hormone therapy and tamoxifen – in collaboration with a number of national and international centres.

Dr. Hadji is a co-author of the ESMO clinical practice guideline for bone health in cancer patients, the German S-III guidelines for the diagnosis and treatment of breast cancer (DGGG), the German S-III guidelines for ONJ (DGMK) , the German Osteoporosis guidelines (DVO), use of HRT in postmenopausal women (DGGG) as well the German guidelines on hormonal contraception (DGGG).

Currently, Dr. Hadji is the vice president of the Dachverband Osteologie (DVO) and a board member of the International Cancer and Bone Society (CABS) as well as the German Menopause Society (DMG). He is additionally an active member of several oncology and osteoporosis societies with a special interest in diagnosis and treatment of bone oncology in women with breast cancer. He has published over 250 peer-reviewed articles and book chapters in these fields. His editorial activities extend to editor in chief of the journal of bone oncology and refereeing for a number of national and international journals.

Roberta-Venturella-pr
Prof. Roberta Venturella, Italy

Roberta Venturella is an Associate Professor of Obstetrics and Gynecology at the Magna Graecia University of Catanzaro and is the Head of the ART Center of Pugliese Ciaccio Hospital.
She received her M.D. Degree from the University of Palermo, School of Medicine, in June 2008.  

Since 2011 she is working in a clinical and scientific collaboration and Training program, particularly focused on fertility preservation techniques in patients with malignant and benign gynecological diseases at the GENERA A.R.T. Centers sited in Naples and Rome.  

On May 2017 she has completed herPhD course at the Magna Graecia University, entitled: “Molecular oncology and translational innovative medical and surgical technologies for fertility preservation”, discussing a PhD thesis entitled: “Prophylactic bilateral salpingectomy and its consequences on ovarian reserve: short and long-term evaluations through innovative diagnostic modalities”.  
In May 2017 she applied as a Research Fellow at the Magna Graecia University and she was also the youngest Italian candidate obtaining the national scientific qualification to function as Associate professor in Italian Universities in 2017. 

Since 2018 she is Associate Professor at the Magna Graecia University and she has obtained in 2019 the national scientific qualification to function as Full professor in Italian Universities. She is also the Head of the first and unique Public Calabrian ART Center, sited in Pugliese Ciaccio Hospital of Catanzaro.  

She is currently involved in many activities related to the fertility awareness and the prevention of infertility.  
Currently, she is involved in many study protocols, focusing her research activity on the effect of medical and surgical therapies on woman ovarian reserve. She is also an active member of ETIC (Endometriosis Treatment Italian Club). 

Zatik-Janos-dr
Chair : Prof. Peyman Hadji, Germany

Prof. Peyman Hadji obtained his medical degree from the University of Frankfurt, Germany, in 1990, and went on to complete his postgraduate training in obstetrics and gynaecology at the Hamburg Institute of Endocrinology and Reproductive Medicine and the Philipps-University of Marburg, where he received his PD in 2001. In June 2006, he was appointed as a full Professor of Medicine at the Philipps-University of Marburg. From 2014-2018, Dr. Hadji was the head of the department of bone oncology, endocrinology and reproductive medicine at the Krankenhaus Nordwest in Frankfurt, Germany. Since October 2018, Dr. Hadji is the head of the Frankfurt Centre of Bone Health.

His current research interest is on the management of women with breast cancer, with a special focus on cancer induced bone loss (CIBL), as well as studies on side-effect management in cancer therapies and outcome research. He is the first author of a recent practical guidance for the management of aromatase inhibitor-associated bone loss of seven international societies. Dr. Hadji is also a co-author of the ESMO 2021 practice guidelines on bone health in cancer patients. He is additonally a co-author of the guidance on the use of bisphosphonates in solid tumours, a consensus recommendation from the second Cambridge conference on advancing treatment for metastatic bone cancer and a clinical experience and treatment recommendation on aromatase inhibitor-induced arthralgia. In addition to this, Dr. Hadji has performed a number of studies on compliance and persistence in oncology and osteoporotic therapies, and is involved in several clinical studies on different pharmacological interventions for osteoporosis including bisphosphonates, denosumab, parathyroid hormones, raloxifene, hormone therapy and tamoxifen – in collaboration with a number of national and international centres.

Dr. Hadji is a co-author of the ESMO clinical practice guideline for bone health in cancer patients, the German S-III guidelines for the diagnosis and treatment of breast cancer (DGGG), the German S-III guidelines for ONJ (DGMK) , the German Osteoporosis guidelines (DVO), use of HRT in postmenopausal women (DGGG) as well the German guidelines on hormonal contraception (DGGG).

Currently, Dr. Hadji is the vice president of the Dachverband Osteologie (DVO) and a board member of the International Cancer and Bone Society (CABS) as well as the German Menopause Society (DMG). He is additionally an active member of several oncology and osteoporosis societies with a special interest in diagnosis and treatment of bone oncology in women with breast cancer. He has published over 250 peer-reviewed articles and book chapters in these fields. His editorial activities extend to editor in chief of the journal of bone oncology and refereeing for a number of national and international journals.

SEUD Rendez-vous #3 - September 28th, 2021

Fibroids and infertility

September 28th, 2021 at 6 PM (GMT+2)

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

PROGRAM

Fibroids and infertility

Chair: Prof. Jacques Donnez (Belgium)

  • Surgery or medical management for fibroid related infertility
    Prof. Attilio Di Spiezio Sardo (Italy)
  • New promising methods for treatment of fibroids in women with fibroid related infertility
    Prof. Helena Kopp Kallner (Sweden)
Register in less than a minute

to have a full and free access

to the SEUD RENDEZ-VOUS!

Lives and replays!

ABOUT THE EXPERTS:
Jacques-Donnez-PR
Chair : Prof. Jacques Donnez, Belgium

Jacques Donnez was born in Tournai (Belgium) on 16 July, 1947. He studied at the Catholic University of Louvain. He defended his PhD thesis in 1984, entitled “The fallopian tube: normal and pathological histophysiology”.
He became Full Professor and Head of the Department Gynaecology and Andrology in 1986. He also founded the Academic Infertility Research Unit of the Catholic University of Louvain in 1986.
He has focused his research activities on three main topics: tubal infertility, endometriosis
and finally, ovarian cryopreservation and transplantation. He published over 700 original articles in peer-review journals. Prof. Donnez was the founding president of ESGE (European Society of Gynecological Endoscopy) and the first president of WES (World Endometriosis Society) Prof. Donnez was the first President of the International Society for Fertility Preservation (ISFP).
He has been elected in February 2009 at the Royal Belgian Academy of Medicine. Since 2012, he is Professor Emeritus at the Catholic University of Louvain and Director of SRI (Société de Recherche pour l’Infertilité) in Brussels.
Member of several SAB (Scientific Advisory Boards), he is still involved in several clinical international multicenter studies on endometriosis and uterine fibroids, and collaborates with the Academic Unit of Prof. M.M. Dolmans, project leader and pioneer in the field of fertility preservation in women.

Attilio-Di-Spiezio-Sardo-PR
Prof. Attilio Di Spiezio Sardo, Italy

Dr Attilio Di Spiezio Sardo obtained his Medical Degree in 2000, Certification in Obstetrics and Gynaecology in 2005 and PhD in Human Development, Reproduction and Growth in 2008. He has been member of the Teaching Faculty at Unit of Minimally Invasive Therapy & Endoscopy Training Centre while at the Royal Free Hospital, London in 2003. Winner in 2008 and 2015 of the Golden Hysteroscope Award for the best scientific paper submitted at the Annual Congress of American Association of Gynecological Endoscopy (AAGL)

Actually he is Full Professor of Obstetrics and Gynecology and Chief of the Hysteroscopy Unit at the Department of Obstetrics and Gynecology, University of Naples “Federico II”, Italy.

Author of more than 200 articles published in international peer-review journals, 1 book on hysteroscopy (translated in English and chinese), 20 book chapters and 1 educational DVD

He has been personally invited as speakers in more than 200 national and international meetings and he has actively organized 30 national and international courses and scientific meetings.

He is member of the Executive Board of the European Society of Gynecological Endoscopy (ESGE) since 2015 and has contributed to the development of the Gynaecological Endoscopic Surgical Education and Assessment (GESEA) program within the ESGE. Actually is Director of the Training and Certification GESEA center of University Federico II of Naples.

Helena-Kopp-Kallner-PR
Prof. Helena Kopp Kallner, Sweden

Helena Kopp Kallner is associate professor at Karolinska Institutet in Sweden and senior consultant in Obstetrics and Gynecology. She is head of the clinical research department and clinical trials unit at the department of Obstetrics and Gynecology at Danderyd Hospital. She has ongoing research in the field of contraception, abortion and fibroids in addition to obstetrics at Karolinska Institutet and is principal investigator of several ongoing clinical studies. She is president of the working group on family planning in Sweden and member of the board of the Swedish Society for Obstetricians and Gynecologists. She is a frequent lecturer on the subject of abortion, contraception and treatment of fibroids.

SEUD Rendez-vous #4 - October 28th, 2021

The concept of balance between efficacy and safety. GnRH antagonist and add-back therapy

October 28th, 2021 at 6 PM (GMT+2)

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

PROGRAM

The concept of balance between efficacy and safety. GnRH antagonist and add-back therapy

Chair: Prof. Roberto Marci (Italy)

  • The therapeutic window of therapy. Hormonal effects, contraception and tolerability
    Dr. Fernanda Águas (Portugal)
  • Effects of therapy on bone mineral density in pre-menopausal women
    Prof. Peyman Hadji (Germany)
Register in less than a minute

to have a full and free access

to the SEUD RENDEZ-VOUS!

Lives and replays!

ABOUT THE EXPERTS:
Roberto-Marci-PR
Chair : Prof. Roberto Marci, Italy

Professor Roberto Marci received his medical degree in 1991 at Rome University “La Sapienza”. In
1995 he completed his residency in obstetrics and gynaecology and then attended for several years
the Unit of Reproductive Medicine and Gynaecological Endocrinology in the Department of
GynaecologyObstetrics, CHUV, University of Lausanne, Switzerland where he received his PhD
degree in 2000. In 2001 he moved to the Unit of Reproductive Medicine and Gynaecological
Endocrinology, Department of GynaecologyObstetrics, University of L’Aquila, Italy, where he held
the position of Assistant Professor. In 2009 he moved as an Associate Professor at Ferrara University
where he developed the Infertility Unit in Arcispedale Sant’Anna Hospital and introduced a special
service for the clinical management of endometriosis. He was Director of Residency School in
Obstetrics and Gynecology, University of Ferrara and Director of Midwifery School in Obstetrics
University of Ferrara. In 2015 he moved to Geneva as an invited Professor at the Geneva University,
Switzerland. He is actually full Professor at the University of Ferrara Dpt of Traslational Medicine
and Scientific Director in the Department of Gynecology in Geneva.
He is an acknowledged reviewer for several scientific journals, In addition to that he has published
150 papers in several national and international scientific journals and he has recently joined the
Editorial Board of many international journals. He is a member of the board of national and
international societies. His main research activity is directed to the study of Reproductive Medicine,
Endocrinological Gynaecology and Endometriosis.

Fernanda-Aguas-pr
Dr. Fernanda Àguas, Portugal

Doctor Fernanda Águas got her degree in medicine at Coimbra University, Portugal, in 1982. She was a resident in Gynecology-Obstetrics for 6 years at the Bissaya-Barreto Maternity, Coimbra Hospital Center. In 2003, she became Director of the Women’s Health Department of the maternity and has been Director of the Gynecology Department, at Hospital and University Coimbra Center, since 2015.

Her areas of special interest are Endocrinological Gynecology and Genital Malformations, General Gynecology, Fibroids and Endometriosis, Menopause, Gynecological ultrasound, Gynecological surgery, and endoscopic surgery techniques.

She has been involved over the years in a number of Scientific societies: Vice President of the Portuguese Menopause Society (2002-2005), Treasurer, then President of the Portuguese Gynecology Society (2002-2013), Council member of the European Board and College of Obstetrics and Gynecology (EBCOG, 2010-2017). She is currently a Board Member of the Portuguese College of Obstetrics and Gynecology (since 2009) and Coordinator of the Clinical Studies Center of the Gynecology Portuguese Society (since 2018).

Dr. Águas has had influential scientific activity: she was a Principal investigator and co-investigator in nine clinical trials, and National coordinator in three clinical trials. She gave more than 70 lectures at Congresses or Conferences, authored more than 50 publications in national and international journals, and coordinated National Consensus Publications on Uterine Myomas, Endometriosis and Abnormal Uterine Bleeding. She has also organized more than 30 scientific meetings and training courses.

Dr. Águas was a member of the scientific board of Portuguese Obstetric and Gynecological Acta, from 2006 to 2018, and has been a reviewer of the Portuguese Medical Acta, since 2010.

Hadji-Peyman-Pr
Chair : Prof. Peyman Hadji, Germany

Prof. Peyman Hadji obtained his medical degree from the University of Frankfurt, Germany, in 1990, and went on to complete his postgraduate training in obstetrics and gynaecology at the Hamburg Institute of Endocrinology and Reproductive Medicine and the Philipps-University of Marburg, where he received his PD in 2001. In June 2006, he was appointed as a full Professor of Medicine at the Philipps-University of Marburg. From 2014-2018, Dr. Hadji was the head of the department of bone oncology, endocrinology and reproductive medicine at the Krankenhaus Nordwest in Frankfurt, Germany. Since October 2018, Dr. Hadji is the head of the Frankfurt Centre of Bone Health.

His current research interest is on the management of women with breast cancer, with a special focus on cancer induced bone loss (CIBL), as well as studies on side-effect management in cancer therapies and outcome research. He is the first author of a recent practical guidance for the management of aromatase inhibitor-associated bone loss of seven international societies. Dr. Hadji is also a co-author of the ESMO 2021 practice guidelines on bone health in cancer patients. He is additonally a co-author of the guidance on the use of bisphosphonates in solid tumours, a consensus recommendation from the second Cambridge conference on advancing treatment for metastatic bone cancer and a clinical experience and treatment recommendation on aromatase inhibitor-induced arthralgia. In addition to this, Dr. Hadji has performed a number of studies on compliance and persistence in oncology and osteoporotic therapies, and is involved in several clinical studies on different pharmacological interventions for osteoporosis including bisphosphonates, denosumab, parathyroid hormones, raloxifene, hormone therapy and tamoxifen – in collaboration with a number of national and international centres.

Dr. Hadji is a co-author of the ESMO clinical practice guideline for bone health in cancer patients, the German S-III guidelines for the diagnosis and treatment of breast cancer (DGGG), the German S-III guidelines for ONJ (DGMK) , the German Osteoporosis guidelines (DVO), use of HRT in postmenopausal women (DGGG) as well the German guidelines on hormonal contraception (DGGG).

Currently, Dr. Hadji is the vice president of the Dachverband Osteologie (DVO) and a board member of the International Cancer and Bone Society (CABS) as well as the German Menopause Society (DMG). He is additionally an active member of several oncology and osteoporosis societies with a special interest in diagnosis and treatment of bone oncology in women with breast cancer. He has published over 250 peer-reviewed articles and book chapters in these fields. His editorial activities extend to editor in chief of the journal of bone oncology and refereeing for a number of national and international journals.

SEUD Rendez-vous #5 - November 25th, 2021

Comprehensive management of uterine fibroids (surgery and Medical option)

November 25th, 2021 at 6 PM (GMT+1)

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

PROGRAM

Comprehensive management of uterine fibroids (surgery and Medical option)

Chair : Dr. Francisco Carmona (Spain)

  • Surgical management of UF
    Prof. Attilio Di Spiezio Sardo (Italy)
  • Medical management of UF and patients’ choices
    Prof. Helena Kopp Kallner (Sweden)
Register in less than a minute

to have a full and free access

to the SEUD RENDEZ-VOUS!

Lives and replays!

ABOUT THE EXPERTS:
Carmona
Chair : Dr. Francisco Carmona, Spain

He has been member of the University of Barcelona’s Department of Obstetrics and Gynaecology as Professor from 2006. His main areas of interest are endometriosis and benign diseases including pelvic floor pathology. He has published more than 100 scientific articles in the most important medical journals both general (as The Lancet and JAMA) and of his speciality (including AJOG, Hum Rep, Fertil Steril and many others). He is also author of more than 20 book chapters both in English and in Spanish. Dr. Carmona acts as invited referee for several important medical journals including Fertility and Sterility and Human Reproduction. He is also member of the Editorial Board of Gynecological Surgery, Journal of Endometriosis and Pelvic Pain Disorders and Medicina Clínica.

He is member of a number of different medical associations including ESGE (he was member of the Board Committee of this society from 2006 to 2010), AAGL (current member of the Advisory Board and past member of the Board of Trustees: 2012-2014), SIAEGI (current member of the Executive Committee), EEL (past member of the Executive Board), SEUD (founding member and Executive Board Member), WES (Ambassador) and the Spanish Gynecologic Endoscopic Society (member of its Grupo de Expertos en Endoscopia).

From the late 1990 he has organized advanced endoscopic courses and workshops on minimally invasive surgery and he was the President of the 19th Congress of the ESGE and President of the 10th International Meeting of the AAGL.

 

Attilio-Di-Spiezio-Sardo-PR
Pr. Attilio Di Spiezio Sardo, Italy

Dr Attilio Di Spiezio Sardo obtained his Medical Degree in 2000, Certification in Obstetrics and Gynaecology in 2005 and PhD in Human Development, Reproduction and Growth in 2008. He has been member of the Teaching Faculty at Unit of Minimally Invasive Therapy & Endoscopy Training Centre while at the Royal Free Hospital, London in 2003. Winner in 2008 and 2015 of the Golden Hysteroscope Award for the best scientific paper submitted at the Annual Congress of American Association of Gynecological Endoscopy (AAGL)

Actually he is Full Professor of Obstetrics and Gynecology and Chief of the Hysteroscopy Unit at the Department of Obstetrics and Gynecology, University of Naples “Federico II”, Italy.

Author of more than 200 articles published in international peer-review journals, 1 book on hysteroscopy (translated in English and chinese), 20 book chapters and 1 educational DVD

He has been personally invited as speakers in more than 200 national and international meetings and he has actively organized 30 national and international courses and scientific meetings.

He is member of the Executive Board of the European Society of Gynecological Endoscopy (ESGE) since 2015 and has contributed to the development of the Gynaecological Endoscopic Surgical Education and Assessment (GESEA) program within the ESGE. Actually is Director of the Training and Certification GESEA center of University Federico II of Naples.

Helena-Kopp-Kallner-PR
Prof. Helena Kopp Kallner, Sweden

Helena Kopp Kallner is associate professor at Karolinska Institutet in Sweden and senior consultant in Obstetrics and Gynecology. She is head of the clinical research department and clinical trials unit at the department of Obstetrics and Gynecology at Danderyd Hospital. She has ongoing research in the field of contraception, abortion and fibroids in addition to obstetrics at Karolinska Institutet and is principal investigator of several ongoing clinical studies. She is president of the working group on family planning in Sweden and member of the board of the Swedish Society for Obstetricians and Gynecologists. She is a frequent lecturer on the subject of abortion, contraception and treatment of fibroids.